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A B S T R A C T
Purpose: The prevalence of nonconvulsive status epilepticus (NCSE) in brain tumor patients is unknown.
Since NCSE has been associated with signiﬁcant mortality and morbidity, early identiﬁcation is essential.
This study describes the clinical and EEG characteristics, treatment, and outcome in brain tumor patients
with NCSE.
Method: All patients admitted to Mount Sinai Hospital from 2009 to 2012 with an ICD-9 brain tumor
code were cross-referenced with the epilepsy department’s database. EEGs from matching patients were
reviewed for NCSE. Relevant information from the medical records of the patients with NCSE was
extracted.
Results: 1101 brain tumor patients were identiﬁed, of which 259 (24%) had an EEG and 24 (2%) had NCSE.
The vast majority of seizures captured were subclinical with 13 patients (54%) having only subclinical
seizures. Treatment resolved the NCSE in 22 patients (92%) with accompanying clinical improvement in
18 (75%) of those patients. Tumor recurrence or progression on MRI was associated with decreased 2-
month survival (75% mortality, p = 0.035) compared to stable tumors (20% mortality). Patients with
metastatic disease had median survival from tumor diagnosis of 1.2 months.
Conclusion: NCSE in brain tumor patients may be under diagnosed due to the frequent lack of outward
manifestations and highly treatable with improvement in the majority of patients. NCSE patients with
progressing brain lesions, tumor recurrence, or metastatic disease are at serious risk of mortality within
2 months. Continuous EEG monitoring in brain tumor patients with recent clinical seizures and/or a
depressed level of consciousness may be critical in providing appropriate care.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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Seizures are commonly associated with brain tumors, with 40–
80% of brain tumor patients experiencing a seizure during the
course of the disease.1 However, the prevalence of nonconvulsive
status epilepticus (NCSE) in these patients is unknown. NCSE was
found in 8% of 236 comatose patients2 and in 6% of cancer patients
with altered mental status but no CNS involvement,3 and is
generally thought to be under diagnosed.4 NCSE can be confused
with altered mental status from other causes, such as tumor
progression, edema, or hemorrhage. While NCSE has been
associated with signiﬁcant mortality5 and neurological morbidity,6
it is not yet clear if early identiﬁcation and treatment improve
outcome. Furthermore, NCSE can be the presenting sign of new* Corresponding author at: 1468 Madison Avenue, New York, NY 10029, USA.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rebrain tumors or metastatic lesions.7,8 Although imaging abnor-
malities have been described in these patients,9,10 there is a
scarcity of data on manifestations, electrographic characteristics,
treatment, and outcomes of NCSE in brain tumor patients.
This retrospective case series describes the characteristics of
brain tumor patients with NCSE and examines which variables
may inﬂuence NCSE duration and overall survival.
2. Methods
2.1. Data collection
This study was approved by the Icahn School of Medicine at
Mount Sinai’s Institutional Review Board. Medical records from
Mount Sinai Hospital were queried from July 1, 2009 to July 1, 2012
for brain tumor International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) codes 191, 198.3, 200.5, 225, and 239.6. These
codes represent primary malignant brain tumors, secondary
malignant brain tumors, primary CNS lymphoma, benign brainserved.
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neoplasms, respectively. These lists were matched with the
epilepsy department’s database containing all EEGs conducted
at the hospital during this time period. EEG recordings of all
matching patients were evaluated to determine if they had NCSE.
All patients with NCSE had continuous EEG monitoring. Medical
records of the identiﬁed patients were reviewed to collect
information on demographics, tumor type and treatment, NCSE
clinical and EEG characteristics, NCSE treatment, radiography, and
overall survival.
2.2. Deﬁnitions
As of yet, there are no widely accepted criteria for the deﬁnition
of NCSE. We deﬁned NCSE as ongoing seizure activity, lasting
>30 min, without generalized convulsions. Patients were de-
scribed as being alert or having a depressed (lethargic, obtunded,
or comatose) level of consciousness.
Two epileptologists (MF, LM) independently reviewed EEGs and
unanimously agreed on inclusion in the study. Seizures were
termed subclinical if there was no deﬁnite outward manifestation
of seizure with the understanding that for some individuals the
seizures were depressing the level of consciousness. For the
purposes of this review the authors delineate NCSE into four
different seizure patterns:
1. Focal nonconvulsive seizures (NCS): A focal onset followed by
clear electrographic evolution. A pattern was said to evolve if
there were at least 2 unequivocal, sequential changes in
frequency, morphology or location as deﬁned by the ACNS
guidelines.11
2. Ictal interictal continuum (IIC): This category was used for ictal
patterns without evolution as deﬁned by the ACNS.11 It is a
convention that lateralized periodic discharges (LPD) faster than
3 Hz represent an ictal pattern.12 In addition, LPD which were
slower in frequency with a clinical correlate or which responded
to treatment with AEDs were considered a pattern of NCSE.12
Rhythmic or spikey theta and alpha activity without evolution
which may wax and wane was placed in this category. Most LPD
were NOT considered a form of NCSE.
3. Epilepsia partialis continua (EPC): Deﬁned as unremitting motor
seizures involving part or all of one side of the body lasting for
hours to days. There is disagreement in the literature regarding
the inclusion of this type of seizure under the category of NCSE.
Ebersole and Pedley12 include EPC in the category of NCSE
whereas Maganti et al.4 exclude motor seizures from NCSE.
Since EPC was seen relatively frequently in this population, the
authors opted to use Ebersole and Pedley’s deﬁnition. EPC was
often without EEG correlate.
4. Generalized nonconvulsive status epilepticus: Generalized
periodic discharges (GPD) 3 Hz or greater on EEG or seizures
with a generalized onset and evolution.Table 1
Categorization of EEG characteristics.
Characteristic Categorization Deﬁnition
Reactivity Reactive Noxious stimulation caused an 
Non-reactive Noxious stimulation did not cau
Organization Good An anterior to posterior gradien
amplitude frequency anteriorly
Fair The EEG lacked an anterior to p
Poor A PDR <6 Hz or no PDR withou
Slowing Generalized-mild Predominant high theta frequen
Generalized-moderate Predominant low theta frequen
Generalized-severe Predominant delta frequency (0
Focal slowing One area of the brain had sloweThe categorization of background EEG characteristics in this
paper is described in Table 1.
2.3. Outcomes and statistics
All variables were tested against two outcomes: NCSE duration
(greater than or less than 24 h) and 2-month survival. Student’s t-
tests were used for continuous variable and chi-squares and
Fisher’s exact test were used for categorical variables. Where
appropriate, linear-by-linear association was used for graded
categorical values. P-values <0.05 were considered signiﬁcant for
this study.
3. Results
A total of 1101 patients were identiﬁed by the queried brain
tumor ICD-9 codes. Of these, 259 (24%) had an EEG and 24 (2%) had
NCSE.
The reason for the continuous EEG was a clinical seizure for 20
(83%) patients and altered mental status for 4 (17%) patients.
3.1. Demographics
There were 12 males and 12 females with a mean age of 62
years (SD 15, range 25–84). Tumor types consisted of 6 primary
benign (4 meningioma, 1 acoustic neuroma, 1 central neurocy-
toma), 10 primary malignant (5 glioblastoma multiforme, 1 high
grade glioma, 2 WHO III anaplastic astrocytoma, 1 WHO grade II
astrocytoma, 1 oligodendroglioma), and 8 secondary malignant (4
lung cancer, 1 breast cancer, 1 multiple myeloma, 1 oral pharynx, 1
unknown primary).
Five patients (21%) had NCSE lasting less than 24 h while 19
patients (79%) had NCSE for greater than 24 h. Eleven (48%)
patients died within 2 months of their episode of NCSE (data
missing for one patient). Age, gender, and tumor type were not
associated with 24-h NCSE duration or 2-month survival.
Median survival time from ﬁrst onset of NCSE was 3 months for
primary benign, 1.9 months for primary malignant, and 1.2 months
for secondary malignant. Median survival time from tumor
diagnosis was 84 months for primary benign, 18 months for
primary malignant, and 1.2 months for secondary malignant.
3.2. NCSE clinical characteristics
Mental status exam showed 2 patients in coma, 10 patients
with obtunded or lethargic mental status, and 12 alert patients.
Alert patients were more likely to have NCSE duration of greater
than 24 h (p = 0.002), however there was no effect on 2-month
survival.
Motor signs (either jerking/twitching or automatisms) were
observed in 10/24 (42%) patients and were nearly signiﬁcantly
correlated with NCSE duration of greater than 24 h (p = 0.053) butincrease in brain wave frequency
se a change in background activity
t with a posterior dominant rhythm (PDR) between 8–12 Hz and a faster lower
osterior gradient and/or there was a slower PDR (6–8 Hz).
t an anterior to posterior gradient
cy (7–8 Hz)
cy (4–7 Hz)
–4 Hz)
r frequencies either intermittently or continuously
Fig. 1. Clinical characteristics of NCSE.
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Seven of these 10 patients had EPC. Motor manifestations were
more common in the alert patients with 8/12 alert patients having
motor manifestations.
Four patients had language disturbances during their NCSE. For
2 of these 4 patients, the language disturbance was a persistent
aphasia which gradually improved (over the course of days) with
treatment of NCSE. All of the patients with a language disturbance
were alert, as language could not be reasonably assessed in
patients with lethargy, obtundation or coma.
The vast majority of the seizures captured were subclinical. Of
the 24 patients, 5 (21%) had clinical seizures only, 6 (25%) had
clinical and subclinical seizures, and 13 (54%) had only subclinical
seizures. For the 6 patients with both clinical and subclinical
seizures, time spent in subclinical status was far longer than the
time spent with clinical seizures. All of the 12 patients with a
depressed level of consciousness had subclinical seizures. Seven of
the 12 patients with an alert mental status had subclinical seizures.
Fig. 1 shows a comparison between the clinical characteristics of
NCSE in alert patients and in those with a depressed level of
consciousness.
Five out of 24 (22%) patients were intubated, however there was
no association with NCSE duration or survival.
3.3. NCSE EEG characteristics
Twelve patients had numerous focal NCS, 10 had NCSE on the
IIC, 7 had EPC, and 3 had seizures with a generalized onset (Fig. 2).
Seven people had more than one seizure pattern. Two of the 70
2
4
6
8
10
12
14
NCS IIC EP C Gener alize d
onset
>1 seizur e
patter n
N
um
ber of paents
Fig. 2. NCSE seizure patterns. NCS: nonconvulsive seizures, IIC: ictal interictal
continuum, EPC: epilepsia partialis continua.patients with EPC had a deﬁnite electrographic correlate (a time
locked LPD) with each jerk.
Eleven patients had seizures classiﬁed as on the IIC. Details of
the seizure patterns can be found in Table 2. Electrographically,
continuous LPD and rhythmic/spikey activity without evolution
were placed in this category. The cessation of this activity tended
to be gradual without a discreet electrographic offset. Clinical
improvement correlated with the electrographic improvement.
More severe generalized slowing (p = 0.017), poorer organiza-
tion (p = 0.024) and non-reactive EEG (p < 0.001) were associated
with less than 24-h NCSE duration. No EEG characteristics were
correlated with 2-month survival.
3.4. NCSE treatment
Patients whose NCSE lasted for more than 24 h had more AEDs
at onset (1.4 vs. 0.6, p = 0.037) and more AEDs during treatment
(3.2 vs. 2.0, p = 0.033) of NCSE. AED use was not associated with 2-
month survival. Speciﬁc AEDs used are detailed in Fig. 3.
Treatment with benzodiazepines, steroids, or continuous
midazolam infusion was not associated with 2-month mortality
or NSCE duration.
Of the 24 people, treatment resolved the NCSE in 22 (92%).
Eighteen (75%) people showed both resolution of the seizures and
improvements in their clinical exam. Four individuals’ (17%) EEG’s
improved with treatment, but their mental status did not improve.
Two (8%) people did not improve clinically or electrographically.
Treatment was essentially interrupted for both of these patients,
one for emergency neurosurgery, and the second for a transfer to
palliative care.
3.5. Radiographic ﬁndings
In the 6 patients with primary benign tumors, 5 had stable
tumors on MRI (missing data for 1 patient). NCSE occurred in the
post-operative period in 4/6 of these patients. Of the 10 patients
with primary malignant disease, 4 had stable tumors, 5 had
progressive tumors, and 1 presented with a new malignant lesion.
Among the 8 patients with metastatic cancer, only 1 had stable
disease while 6 showed new brain lesions and 1 did not have prior
MRI on record for comparison in the setting of established
metastases.
Having a new or progressing lesion on MRI was associated with
a decreased 2-month survival (p = 0.030). Patients with new or
progressing lesions had 75% (9/12) mortality at two months, while
those with stable disease had a two-month mortality of 20% (2/10).
4. Discussion
This is one of the ﬁrst studies, and the largest to date, to
examine NCSE in patients with brain tumors. In this study, NCSE
was found in 2% of all patients with brain tumors admitted to
Mount Sinai Hospital over a three-year period.
Nineteen (79%) out of 24 patients with NCSE had subclinical
seizures, including all 12 patients with a depressed level of
consciousness. Six of these 19 patients had both subclinical and
clinical seizures. This suggests that we underestimate NCSE, as we
cannot rely on outward manifestation of seizure activity for
detection. Furthermore, clinical seizures represent the tip of the
iceberg in terms of seizure activity.
NCSE duration of greater than 24 h was statistically associated
with a number of ﬁndings including: (1) a more alert mental status,
(2) less generalized slowing on EEG, (3) better EEG organization,
(4) a reactive EEG, (5) presence of motor signs during seizure
activity, (6) more AEDs at onset of NCSE, and (7) more AEDs during
NCSE treatment. Despite the NCSE, these patients were not
Table 2
Seizure patterns of brain tumor patients in NCSE.
Age and
gender
Age at
diagnosis
of tumor
Reason for
EEG
Status
for >24 h
LOC
during
NCSE
Seizure type(s) Progression of
tumor on MRI at
the time of NCSE
Survival
after NCSE
Primary benign
M72 65 Clinical
seizure
Yes Alert Focal NCS:
Subclinical: Hundreds of seizures of R FT origin.
Clinical: Occasional focal seizures of R FT origin with L arm
jerking and behavioral interruption.
No D 1 month
M74 68 Clinical
seizure
Yes Alert Focal NCS:
Subclinical: Twelve R FT seizures.
IIC:
Subclinical: Fluctuating R FT 1–2 Hz LPD+ R, lasting for several
days.
No D 4 months
F70 70 Clinical
seizure
Yes Alert IIC:
Subclinical: Fluctuating 3–4 Hz L posterior LPD + F/R.
No A 4+ months
F73 73 AMS Yes Coma Electrographic generalized seizures:
Subclinical: Continuous 3 Hz GPD + R without evolution.
No D 3 months
M84 83 Clinical
seizure
No Obtunded Electrographic generalized seizures:
Subclinical: Continuous 3–4 Hz GPD + F.
No comparison
study
D 3 months
F33 32 Clinical
seizure
Yes Alert IIC:
Subclinical: LH with 1–2 seconds of higher amplitude bursts of
sharp waves followed by 1–2 seconds of relative attenuation.
No A 9+ months
Primary malignant
F25 21 Clinical
seizure
Yes Alert EPC:
Very frequent rhythmic L arm jerking lasting several minutes in
sleep and wake. No EEG correlate.
No A 28+ months
F41 35 Clinical
seizure
Yes Alert Focal NCS:
Clinical: Seventy-four seizures of LF origin. Clinically takes a
deep breath and is then unable to speak. Occasional R cheek
twitching.
No A 28+ months
M57 56 AMS Yes Obtunded Focal NCS:
Subclinical: Eighty-eight focal seizures of L posterior quadrant
origin.
Yes D 11 months
F57 55 Clinical
seizure
Yes Obtunded Focal NCS:
Clinical: Two seizures of RH origin with a L head turn and R
hand automatisms.
Subclinical: Twenty-four seizures of RH origin.
IIC:
Subclinical: Fluctuating continuous 1–4 Hz R LPD + F
Yes D 1 month
M61 60 Clinical
seizure
Yes Alert Focal NCS:
Subclinical: Nine discreet seizures of R FT origin.
Yes D 1 month
F70 69 AMS No Obtunded IIC:
Subclinical: Fluctuating pattern of semi-rhythmic LF fast
activity which waxes and wanes without clear evolution or
spread.
Yes D 2 months
F61 61 Clinical
seizure
No Obtunded Focal NCS:
Subclinical: Forty-two seizures of R FT origin.
IIC:
Subclinical: Continuous 1–2 Hz R LPD + F
GBM diagnosed
at time of NCSE.
A 28+ months
M53 52 Clinical
seizure
Yes Alert Focal NCS:
Subclinical: A single LH seizure.
IIC:
Subclinical: Near continuous focal 1–2 Hz LH LPD + F. EEG with
relative suppression between sharp waves. Correlates with
aphasia which improves with AEDs.
EPC:
Cheek twitching in sleep and wake not time-locked to the above
LPD.
Yes D 1 month
M83 82 Clinical
seizure
Yes Obtunded Focal NCS:
Subclinical: Over 90 focal LH seizures.
EPC:
Near continuous subtle R arm and leg jerking in wake and sleep
without correlation to EEG.
No D 2 months
F68 68 Clinical
seizure
Yes Alert EPC:
Near continuous subtle R lip and cheek twitching in sleep and
wake, EEG negative.
No A 12+ months
Secondary malignant
M55 55 Clinical
seizure
No Coma Focal NCS:
Subclinical: Sixty-seven seizures. 64 with RH onset and 3 with a
LH onset.
Seizures began after 37 h of monitoring.
No comparison
study.
D 1 month
F82 F81 Clinical
seizure
No Obtunded IIC:
Subclinical: Continuous RH focal status epilepticus with semi-
rhythmic high amplitude theta and alpha without clear
evolution.
No A 8 months
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Table 2 (Continued )
Age and
gender
Age at
diagnosis
of tumor
Reason for
EEG
Status
for >24 h
LOC
during
NCSE
Seizure type(s) Progression of
tumor on MRI at
the time of NCSE
Survival
after NCSE
F51 48 Clinical
seizure
Yes Alert IIC:
Subclinical: EEG with near continuous focal LH seizure activity
with ﬂuctuating 1–3 Hz LPDs + F as well as periods without LPDs
but with semi-rhythmic LP spikey theta and alpha. No deﬁnite
evolution.
Yes D 2 months
M58 Unknown Clinical
seizure
Yes Obtunded Focal NCS:
Subclinical: Four seizures of RH origin
IIC:
Subclinical: RH 1 Hz LPD + F alternating with RH spikey alpha
activity lasting for up to several seconds without evolution.
Yes Unknown
F68 Unknown AMS Yes Obtunded Focal NCS:
Subclinical: Fifty LH seizures
EPC:
R facial twitching not time locked to LH 1 Hz LPDs.
Yes D 1 month
M63 59 Clinical
seizure
Yes Alert EPC:
Continuous R eye twitching in sleep and wake, time locked to L
LPD.
Yes D 1 month
M70 Unknown Clinical
seizure
Yes Alert EPC:
R facial twitching time locked to 0.5–1 Hz L LPD + F.
Yes A 8 months
M52 Unknown Clinical
seizure
Yes Obtunded Electrographically generalized onset:
Subclinical: GPD at 3–4 Hz.
Yes D 1 month
LOC: level of consciousness, NCS: nonconvulsive seizures, IIC: ictal interictal continuum, EPC: epilepsia partialis continua, L: left, R: right, FT: frontal temporal, F: frontal, H:
hemisphere, D: deceased, A: alive, LPD: lateralized periodic discharges, GPD: generalized periodic discharges, +F: superimposed fast activity, +R: superimposed rhythmic
activity.
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likely because the risk/beneﬁt analysis by the treating team was
deemed to favor a more conservative, less aggressive management,
perhaps because these patients were alert with well organized
EEGs. A greater number of AEDs at onset and during treatment
indicates that these patients may have had previously established
epilepsy that was more treatment resistant. This supports Brophy
et al.’s description of two clinical phenotypes in NCSE: NCSE in the
context of previously established epilepsy and NCSE with severely
impaired mental status in an acutely ill patient.13 Continuous
motor seizures, particularly EPC, are known to be refractory to
treatment,14 therefore it is not surprising that seizures with motor
signs lasted more than 24 h and that more AEDs were used to gain
control. Not uncommonly 4 or more medications are tried in these
patients.15
The 2-month mortality of patients with NCSE was 48%. The
most important difference between patients who died within 2Fig. 3. Anti-epilemonths of NCSE and those who lived, in many cases, well beyond 2
months was the presence of new or progressing brain lesions on
MRI. An astounding 75% of patients with new or progressing brain
lesions died within 2 months. Many studies have described status
epilepticus as a presenting sign of a new or progressing lesion9,16,17
but this is the ﬁrst to note its strong negative implications for
survival. Neuroimaging is warranted in patients with NCSE with a
history of brain tumor and in patients with NCSE with no
discernible cause.
NCSE may also be associated with decreased survival time from
tumor diagnosis. Patients with primary malignant tumors had a
median survival time of 18 months, which at ﬁrst glance seems
consistent with historical data for GBM. However, in this study,
only 5/10 patients with primary malignant tumors had GBM while
the other 5 had grade II or grade III gliomas, possibly indicating that
survival may be negatively affected by the presence of NCSE. Those
with secondary malignant tumors had a median survival of onlyptic drugs.
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metastatic brain tumors.18 Although the sample size is small, it
indicates a trend toward NCSE being a poor prognostic factor for
overall survival in all tumor types, particularly in metastatic brain
lesions. This could be due to NCSE synergistically affecting the
outcome, as has been found in a stroke and status epilepticus
population,19 or it may be that NCSE is a herald for advancing
disease with no direct impact on survival.
This data suggests that NCSE is highly treatable in this
population. The NCSE resolved in 22 of the 24 patients with
improvement in overall level of function in 18 of the 24 patients.
Even outside of overall prognosis, diagnosis and treating NCSE may
be an important way to improve quality of life.
This study underscores the importance of recognizing NCSE in
the brain tumor population. With proper EEG screening of high-
risk patients in a hospital setting, NCSE can be more readily
identiﬁed. Given this data, all patients with a depressed level of
consciousness and a brain tumor should be considered at risk for
NCSE. Identifying NCSE is critical as it is a reversible cause of
impaired mental status.
This study has a number of limitations. The main one is the
relatively small sample size, as it provides limited statistical power
to ﬁnd differences and precludes more complex multivariate
regression analysis. The second limitation is that this is a
retrospective design, which hinders the ability to understand
outcomes. In this review, NCSE resolved in a high percentage of the
patients with treatment (92%). Most (75%) of the patients
improved clinically as well. However, without a double blind
randomized design, conclusions regarding the beneﬁt of treating
NCSE are difﬁcult to draw. The third limitation of this paper is the
referral bias. The majority of the patients in NCSE were referred for
continuous EEG because of a clinical seizure. Once connected to
VEEG, the vast majority of seizures were subclinical. All of the
patients with a depressed level of consciousness had subclinical
seizures. A reasonable avenue for further research is a prospective
trial designed to determine with continuous EEG the incidence of
NCSE in brain tumor patients with a depressed level of
consciousness. A prospective continuous EEG trial on brain tumor
patients with altered mental status would aid in the determination
of the impact NCSE has on morbidity and mortality.
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